Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.

Maertens J, Cordonnier C, Jaksch P, Poiré X, Uknis M, Wu J, Wijatyk A, Saliba F, Witzke O, Villano S.

N Engl J Med. 2019 Sep 19;381(12):1136-1147. doi: 10.1056/NEJMoa1714656.

PMID:
31532960
2.

Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Jaimes-Albornoz D, Mannone L, Nguyen-Quoc S, Chalandon Y, Chevallier P, Mohty M, Meunier M, Robin M, Ledoux MP, Guillerm G, Bay JO, Poiré X, Maillard N, Leclerc M, Daguindau E, Beguin Y, Rubio MT, Gyan E.

Biol Blood Marrow Transplant. 2019 Jul 19. pii: S1083-8791(19)30445-8. doi: 10.1016/j.bbmt.2019.07.013. [Epub ahead of print]

PMID:
31326611
3.

Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, Reményi P, Blaise D, Schaap N, Trneny M, Passweg J, Porras RP, Cahn JY, Musso M, Poiré X, Fenk R, Itälä-Remes M, Pavone V, Fouillard L, Maertens J, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N.

Biol Blood Marrow Transplant. 2019 Jul 6. pii: S1083-8791(19)30436-7. doi: 10.1016/j.bbmt.2019.07.004. [Epub ahead of print]

PMID:
31288095
4.

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2019 Jul 5. pii: S1083-8791(19)30418-5. doi: 10.1016/j.bbmt.2019.06.034. [Epub ahead of print]

PMID:
31284069
5.

Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.

Nagler A, Labopin M, Dholaria B, Niittyvuopio R, Maertens J, Poiré X, Cornelissen J, Reményi P, Bourhis JH, Beguin Y, Malladi R, Kerre T, Schroyens W, Savani BN, Mohty M.

Blood Adv. 2019 Jul 9;3(13):1950-1960. doi: 10.1182/bloodadvances.2019000030.

6.

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT.

Poiré X, Labopin M, Polge E, Forcade E, Ganser A, Volin L, Michallet M, Blaise D, Yakoub-Agha I, Maertens J, Richard Espiga C, Cornelissen J, Finke J, Mohty M, Esteve J, Nagler A; Acute Leukemia Working Party of the EBMT.

Haematologica. 2019 May 2. pii: haematol.2019.216168. doi: 10.3324/haematol.2019.216168. [Epub ahead of print]

7.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, Knelange NS, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Sep;104(9):1782-1788. doi: 10.3324/haematol.2018.205211. Epub 2019 Feb 7.

8.

Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres.

Poirel HA, Vanspauwen M, Macq G, De Geyndt A, Maertens J, Willems E, Selleslag D, Poiré X, Theunissen K, Graux C, Kerre T, Zachée P, Meuleman N, De Becker A, Verlinden A, Van Obbergh F, Schuermans C, De Wilde V, Jaspers A, Pranger D, Deeren D, Van Riet I, Vaes E, Beguin Y; Belgian Transplant Registry and the Belgian Haematological Society’s Transplant committee.

Bone Marrow Transplant. 2019 Sep;54(9):1434-1442. doi: 10.1038/s41409-019-0458-8. Epub 2019 Jan 29.

PMID:
30696999
9.

Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis.

Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten HC, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt ZN, Zuckerman T, Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Jun;104(6):1230-1236. doi: 10.3324/haematol.2018.201400. Epub 2019 Jan 17.

10.

[Donor Lymphocyte Infusions (DLI): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

De Vos J, Baudoux E, Bay JO, Calmels B, Cras A, El Cheikh J, Guerout-Verite MA, Lacassagne MN, Lamure S, Letellier C, Menard AL, Daguindau E, Poiré X, Yakoub-Agha I, Guillaume T.

Bull Cancer. 2019 Jan;106(1S):S35-S39. doi: 10.1016/j.bulcan.2018.10.002. Epub 2018 Dec 20. French.

PMID:
30580911
11.

Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT.

Giebel S, Labopin M, Czerw T, Socié G, Blaise D, Ghavamzadeh A, Passweg J, Ljungman P, Poiré X, Chevallier P, Reményi P, Rambaldi A, Anafasyev B, Fegueux N, Rovira M, Itälä-Remes M, Bornhäuser M, Mohty M, Nagler A.

Eur J Cancer. 2019 Jan;106:212-219. doi: 10.1016/j.ejca.2018.11.003. Epub 2018 Dec 6.

PMID:
30528805
12.

Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission.

Poiré X, Labopin M, Polge E, Blaise D, Chevallier P, Maertens J, Deconinck E, Forcade E, Rambaldi A, Baerlocher GM, Zuckerman T, Volin L, Schouten HC, Ifrah N, Mohty M, Esteve J, Nagler A.

Am J Hematol. 2019 Feb;94(2):231-239. doi: 10.1002/ajh.25355. Epub 2018 Dec 10.

PMID:
30456896
13.

[Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Yafour N, Couturier MA, Azarnoush S, Girault S, Hermet E, Masouridi Levrat S, Schmidt A, Michallet M, Etancelin P, Guillaume T, Malard F, Sirvent A, Yakoub-Agha I, Poiré X.

Bull Cancer. 2019 Jan;106(1S):S40-S51. doi: 10.1016/j.bulcan.2018.05.018. Epub 2018 Nov 6. Review. French.

PMID:
30409466
14.

The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial.

Schoemans HM, Goris K, Van Durm R, Fieuws S, De Geest S, Pavletic SZ, Im A, Wolff D, Lee SJ, Greinix H, Duarte RF, Poiré X, Selleslag D, Lewalle P, Kerre T, Graux C, Baron F, Maertens JA, Dobbels F; EBMT Transplantation Complications Working party.

Haematologica. 2018 Oct;103(10):1698-1707. doi: 10.3324/haematol.2018.190777. Epub 2018 Jun 14.

15.

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT.

Giebel S, Labopin M, Potter M, Poiré X, Sengeloev H, Socié G, Huynh A, Afanasyev BV, Schanz U, Ringden O, Kalhs P, Beelen DW, Campos AM, Masszi T, Canaani J, Mohty M, Nagler A.

Eur J Cancer. 2018 Jun;96:73-81. doi: 10.1016/j.ejca.2018.03.018. Epub 2018 Apr 18.

PMID:
29679774
16.

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.

Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, Finke J, Poiré X, Maillard N, Milpied N, Yakoub-Agha I, Koh M, Kröger N, Nagler A, Koc Y, Dietrich S, Montoto S, Dreger P.

Bone Marrow Transplant. 2018 May;53(5):617-624. doi: 10.1038/s41409-017-0067-3. Epub 2018 Jan 15.

PMID:
29335632
17.

Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Gauthier J, Poiré X, Gac AC, Leclerc M, Guillaume T, Chalandon Y, Nguyen S, Forcade E, Régny C, Bay JO, Bazarbachi A, Rohrlich PS, Huynh A, Farhi J, Marchand T, Malfuson JV, Pilorge S, Labussière-Wallet H, Renard C, Fornecker LM, Detrait M, Duléry R, Delage J, Ménard AL, Charbonnier A, Nelken B, Jubert C, Suarez F, de la Tour RP, Beguin Y, Schoemans H, Blaise D, Yakoub-Agha I.

Bone Marrow Transplant. 2018 Apr;53(4):400-409. doi: 10.1038/s41409-017-0018-z. Epub 2018 Jan 12.

18.

Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers.

Vallet N, de Fontbrune FS, Loschi M, Desmier D, Villate A, Barraco F, Chevallier P, Terriou L, Yakoub-Agha I, Ruggeri A, Mohty M, Maillard N, Rohrlich PS, Ceballos P, Nguyen S, Poiré X, Guillerm G, Tabrizi R, Farhi J, Devillier R, Rubio MT, Socié G, de Latour RP; Société Francophone de Greffe de Moelle et Thérapie Cellulaire.

Haematologica. 2018 Mar;103(3):e103-e105. doi: 10.3324/haematol.2017.182360. Epub 2017 Dec 21. No abstract available.

19.

Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Poiré X, Labopin M, Polge E, Passweg J, Craddock C, Blaise D, Cornelissen JJ, Volin L, Russell NH, Socié G, Michallet M, Fegueux N, Chevallier P, Brecht A, Hunault-Berger M, Mohty M, Esteve J, Nagler A.

Haematologica. 2018 Feb;103(2):256-265. doi: 10.3324/haematol.2017.178251. Epub 2017 Dec 14.

20.

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.

Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poiré X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti GJ, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2018 Mar;24(3):507-513. doi: 10.1016/j.bbmt.2017.11.017. Epub 2017 Nov 28.

21.

[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Yafour N, Beckerich F, Bulabois CE, Chevallier P, Daguindau É, Dumesnil C, Guillaume T, Huynh A, Levrat SM, Menard AL, Michallet M, Pautas C, Poiré X, Ravinet A, Yakoub-Agha I, Bazarbachi A.

Bull Cancer. 2017 Dec;104(12S):S84-S98. doi: 10.1016/j.bulcan.2017.05.009. Epub 2017 Nov 26. Review. French.

PMID:
29179894
22.

How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome.

Yafour N, Beckerich F, Bulabois CE, Chevallier P, Daguindau E, Dumesnil C, Guillaume T, Huynh A, Masouridi Levrat S, Menard AL, Pautas C, Poiré X, Ravinet A, Michallet M, Bazarbachi A.

Curr Res Transl Med. 2017 Apr - Jun;65(2):65-69. doi: 10.1016/j.retram.2017.06.001. Epub 2017 Jul 4. Review.

PMID:
28687223
23.

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, Bouabdallah R, Bay JO, Nicolas-Virelizier E, McQuaker G, Rossi G, Johnson R, Huynh A, Ceballos P, Rambaldi A, Bachy E, Malladi R, Orchard K, Pohlreich D, Tilly H, Bonifazi F, Poiré X, Guilhot F, Haenel A, Crawley C, Metzner B, Gribben J, Russell NH, Damaj G, Thomson K, Dreger P, Montoto S.

Bone Marrow Transplant. 2017 Aug;52(8):1120-1125. doi: 10.1038/bmt.2017.88. Epub 2017 May 22.

PMID:
28530668
24.

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T.

J Clin Oncol. 2017 Jul 1;35(19):2157-2164. doi: 10.1200/JCO.2016.70.7349. Epub 2017 May 2.

25.

Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Poiré X, Labopin M, Maertens J, Yakoub-Agha I, Blaise D, Ifrah N, Socié G, Gedde-Dhal T, Schaap N, Cornelissen JJ, Vigouroux S, Sanz J, Michaux L, Esteve J, Mohty M, Nagler A.

J Hematol Oncol. 2017 Jan 18;10(1):20. doi: 10.1186/s13045-017-0393-3.

26.

Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.

Robinson SP, Boumendil A, Finel H, Blaise D, Poiré X, Nicolas-Virelizier E, Or R, Malladi R, Corby A, Fornecker L, Caballero D, Pohlreich D, Nagler A, Thieblemont C, Finke J, Bachy E, Vincent L, Schroyens W, Schouten H, Dreger P.

Bone Marrow Transplant. 2016 Mar;51(3):365-71. doi: 10.1038/bmt.2015.286. Epub 2015 Nov 30.

PMID:
26618550
27.

Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).

Poiré X, Labopin M, Cornelissen JJ, Volin L, Richard Espiga C, Veelken JH, Milpied N, Cahn JY, Yacoub-Agha I, van Imhoff GW, Michallet M, Michaux L, Nagler A, Mohty M.

Am J Hematol. 2015 Aug;90(8):719-24. doi: 10.1002/ajh.24069. Erratum in: Am J Hematol. 2016 May;91(5):E301.

28.

High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation.

Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, Blaise D, Finke J, Pflüger KH, Veelken H, Gorin NC, Poiré X, Ganser A, Dreger P, Sureda A.

Leuk Lymphoma. 2015;56(12):3295-300. doi: 10.3109/10428194.2015.1037764. Epub 2015 Aug 26.

PMID:
25899403
29.

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.

Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL Group.

Cancer. 2015 Jul 15;121(14):2393-9. doi: 10.1002/cncr.29389. Epub 2015 Apr 6.

30.

Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.

Sahebi F, Iacobelli S, Biezen AV, Volin L, Dreger P, Michallet M, Ljungman PT, de Witte T, Henseler A, Schaap NP, López-Corral L, Poire X, Passweg J, Hamljadi RM, Thomas SH, Schonland S, Gahrton G, Morris C, KrÖger N, Garderet L.

Bone Marrow Transplant. 2015 Jun;50(6):802-7. doi: 10.1038/bmt.2015.45. Epub 2015 Mar 23.

PMID:
25798673
31.

Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis.

Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, Poiré X, Kobbe G, Narni F, Cortelezzi A, Olavarría E, Schmitz N, Sureda A, Dreger P.

J Clin Oncol. 2014 Oct 10;32(29):3347-8. doi: 10.1200/JCO.2014.57.5597. Epub 2014 Aug 25. No abstract available.

PMID:
25154828
32.

Budd-Chiari syndrome in a patient with acute promyelocytic leukaemia.

Havelange V, Annet L, Poiré X, Lambert C, Vekemans MC.

Br J Haematol. 2014 Jul;166(1):1. doi: 10.1111/bjh.12868. Epub 2014 Apr 2. No abstract available.

PMID:
24690122
33.

A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality.

Labopin M, Gorin NC, Polge E, Socié G, Gurman G, Gluckman E, Jindra P, Poiré X, Schäfer-Eckart K, Ruutu T, Milone G, Arcese W, Mohty M, Rocha V; Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2014 Mar;49(3):376-81. doi: 10.1038/bmt.2013.178. Epub 2013 Nov 18.

PMID:
24241579
34.

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O.

Clin Cancer Res. 2014 Jan 15;20(2):490-8. doi: 10.1158/1078-0432.CCR-13-1311. Epub 2013 Oct 31.

35.

Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.

Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W.

Leuk Lymphoma. 2014 Jul;55(7):1523-32. doi: 10.3109/10428194.2013.842985. Epub 2014 Feb 4.

36.

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.

Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M.

J Clin Oncol. 2013 Oct 1;31(28):3549-56. doi: 10.1200/JCO.2013.48.8114. Epub 2013 Aug 26.

PMID:
23980086
37.

Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.

Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, Chen IM, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson RA, Powell BL, Appelbaum FR, Paietta E, Willman CL, Stock W.

Blood. 2012 Sep 6;120(10):2098-108. doi: 10.1182/blood-2012-01-407601. Epub 2012 Jun 25.

38.

Alemtuzumab in allogeneic hematopoetic stem cell transplantation.

Poiré X, van Besien K.

Expert Opin Biol Ther. 2011 Aug;11(8):1099-111. doi: 10.1517/14712598.2011.592824. Epub 2011 Jun 27.

39.

Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.

Poiré X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM.

Leuk Lymphoma. 2010 Jul;51(7):1241-50. doi: 10.3109/10428194.2010.486876.

PMID:
20496994
40.

Diffuse xanthomatosis as a presenting feature of multiple myeloma.

Segner S, Theate I, Poiré X, Tennstedt D, Marot L, Caers J.

Eur J Haematol. 2010 May;84(5):460-1. doi: 10.1111/j.1600-0609.2009.01400.x. Epub 2009 Dec 15. No abstract available.

PMID:
20015339
41.

Autologous transplant for primary mediastinal B-cell lymphoma.

Poiré X, van Besien K.

Expert Rev Hematol. 2009 Feb;2(1):31-6. doi: 10.1586/17474086.2.1.31.

PMID:
21082992
42.

Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.

Poiré X, Artz A, Larson RA, Kline J, Odenike O, Rich E, Godley L, Stock W, van Besien K.

Leuk Lymphoma. 2009 Jan;50(1):85-91. doi: 10.1080/10428190802626624.

43.

Positive regulation of deoxycytidine kinase activity by phosphorylation of Ser-74 in B-cell chronic lymphocytic leukaemia lymphocytes.

Smal C, Van Den Neste E, Maerevoet M, Poiré X, Théate I, Bontemps F.

Cancer Lett. 2007 Aug 8;253(1):68-73. Epub 2007 Mar 9.

PMID:
17350163

Supplemental Content

Support Center